an anti-alpha5beta1 integrin antibody as anti-angiogenic agent
Networked: 12 relevant articles (0 outcomes, 6 trials/studies)

Bio-Agent Context: Research Results


1. Bhaskar, Vinay: 2 articles (02/2008 - 01/2007)
2. Wales, Pauline E: 2 articles (02/2008 - 01/2007)
3. Ramakrishnan, Vanitha: 2 articles (02/2008 - 01/2007)
4. Fox, Melvin: 2 articles (02/2008 - 01/2007)
5. Tsao, L C: 1 article (01/2013)
6. Besse, B: 1 article (01/2013)
7. Chao, D T: 1 article (01/2013)
8. Soria, J-C: 1 article (01/2013)
9. Almokadem, S: 1 article (01/2013)
10. Fang, Y: 1 article (01/2013)

Related Diseases

1. Neoplasms (Cancer)
2. Carcinoma (Carcinomatosis)
01/01/2007 - "An inhibitor of this integrin, volociximab (M200), inhibits endothelial cell growth and movement in vitro, independent of the growth factor milieu, and inhibits tumor growth in vivo in the rabbit VX2 carcinoma model. "
02/01/2008 - "Because volociximab does not cross-react with rodent alpha5beta1, the syngeneic rabbit VX2 carcinoma model was utilized as an alternative to standard mouse xenograft models for the assessment of anti-tumor activity of volociximab. "
01/01/2008 - "The studies discussed here include the following: i) a phase I study of a chemotherapy doublet gemcitabine plus capecitabine, combined with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma (abstract #141); ii) a phase II study of gemcitabine, bevacizumab, and erlotinib in locally advanced and metastatic adenocarcinoma of the pancreas (abstract #151); iii) final results of the multicenter phase II study on gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer (abstract #198); iv) interim results from a phase II study of volociximab in combination with gemcitabine in patients with metastatic pancreatic cancer (abstract #142); v) a pilot study of combination chemotherapy with S-1 and irinotecan for advanced pancreatic cancer (abstract #155); vi) a multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer (abstract #212); vii) a phase I/II study of PHY906 plus capecitabine in patients with advanced pancreatic carcinoma (abstract #260); and viii) the final results of a phase II trial of Genexol-PM(R), a novel cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (abstract #269). "
3. Renal Cell Carcinoma (Grawitz Tumor)
4. Pancreatic Neoplasms (Pancreatic Cancer)
5. Melanoma (Melanoma, Malignant)

Related Drugs and Biologics

1. Paclitaxel (Taxol)
2. bevacizumab
3. erlotinib (CP 358,774)
4. Carboplatin (JM8)
5. Platinum
6. Fibronectins (Fibronectin)
7. Carbon Monoxide
8. PHY 906
9. capecitabine (Xeloda)
10. S 1 (combination)

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)
2. Combination Drug Therapy (Combination Chemotherapy)
3. Drug Therapy (Chemotherapy)
4. Stents